1,81 €
0,01 % gestern
L&S, 30. Oktober, 22:53 Uhr
ISIN
US00972D1054
Symbol
AKBA
Berichte

Akebia Therapeutics, Inc. Aktie News

Neutral
GlobeNewsWire
etwa 12 Stunden alt
CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2025, on Monday, November 10, 2025, prior to the open of financial markets.
Neutral
GlobeNewsWire
2 Tage alt
Akebia does not expect to initiate VALOR clinical trial following Type C meeting feedback from U.S. FDA Akebia does not expect to initiate VALOR clinical trial following Type C meeting feedback from U.S. FDA
Neutral
GlobeNewsWire
10 Tage alt
Presentations Detail Ongoing Vafseo® (Vadadustat) Real-World Studies and Explore Insights Regarding Clinical Benefits and Dosing of Vafseo Presentations Detail Ongoing Vafseo® (Vadadustat) Real-World Studies and Explore Insights Regarding Clinical Benefits and Dosing of Vafseo
Neutral
GlobeNewsWire
29 Tage alt
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted seven newly-hired employees options to purchase an aggregate of 204,163 shares of Akebia's common stock on September 30, 2025. The options were granted as an inducement material to each emplo...
Neutral
Seeking Alpha
etwa 2 Monate alt
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 8:00 AM EDT Company Participants Erik Ostrowski - Chief Business Officer, Senior VP, CFO & Treasurer Nicholas Grund - Senior VP & Chief Commercial Officer Presentation Unknown Analyst Good morning and thank you for joining us here today at the Wells Fargo Healthcare Conference. I'm join...
Neutral
GlobeNewsWire
etwa 2 Monate alt
CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 95,100 shares of Akebia's common stock on August 29, 2025. The options were granted as an inducement material to each employee...
Positiv
Seeking Alpha
2 Monate alt
I'm bullish on Akebia at $3.13, viewing the 21% post-earnings dip as a buying opportunity ahead of major revenue catalysts. Vafseo's rapid adoption and DaVita's pilot could double Akebia's addressable dialysis market, driving significant near-term revenue growth and profitability. Despite a mixed EPS, strong topline growth and stable Auryxia sales highlight Akebia's transition from speculative ...
Neutral
GlobeNewsWire
2 Monate alt
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its executives will participate in two investor conferences in September: Wells Fargo Healthcare Conference on September 3-5, 2025 in Boston and H.C.

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen